Cancer Conference Update


	Rowan T Chlebowski, MD, PhD Professor of Medicine David Geffen School of Medicine at UCLA Chief, Medical Oncology Harbor-UCLA Medical Center Torrance, California Click here to download the entire interview		MP3

Track 1

Introduction

Track 2

Updated ARNO trial results: Survival advantage in switching from tamoxifen to anastrozole

Track 3

Relative efficacy of up-front, switching or sequencing strategies with tamoxifen and aromatase inhibitors

Track 4

Safety and tolerability of aromatase inhibitors compared to tamoxifen

Track 5

Updated analysis of bone density and fracture risk in the ATAC trial

Track 6

Clinical features of joint symptoms in the ATAC trial

Track 7

Women’s Health Initiative trial of calcium with vitamin D: Effects on breast cancer and arthralgias

Track 8

Potential rationale for the impact of vitamin D and calcium on breast cancer incidence

Track 9

Women’s Intervention Nutrition Study of dietary fat reduction

Track 10

Denosumab (AMG 162) for patients with bone metastases

Track 11

Impact of exercise on body composition, fat distribution and weight in breast cancer survivors

Track 12

Feasibility of implementing lifestyle interventions for patients

Track 13

Potential mechanism of action of exercise on breast cancer recurrence

Track 14

Patient adherence to hormonal therapy

Track 15

Observational study of adjuvant hormonal therapy and “typical” oncology discussions

Track 16

Discussing the cost of hormonal therapy with patients

Track 17

Effect of vitamin D deficiency on bone health during adjuvant treatment with aromatase inhibitors

Track 18

Updated analysis of the MA17 trial


	Antonio C Wolff, MD Associate Professor of Oncology Breast Cancer Program The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland Click here to download the entire interview		MP3

Track 1

Introduction

Track 2

Gene expression profiles from formalin-fixed, paraffin-embedded core biopsies predict docetaxel sensitivity

Track 3

Strategies to identify predictors of response to chemotherapy

Track 4

Toxicity of adjuvant chemotherapy in older and younger patients

Track 5

BCIRG 007: First-line trastuzumab and docetaxel with or without carboplatin

Track 6

Congestive heart failure in older women treated with anthracycline-containing regimens

Track 7

Left ventricular function after adjuvant chemotherapy in the MA5 study

Track 8

Clinical implications of anthracycline-associated cardiotoxicity

Track 9

Taxit-216: Sequential epirubicin, docetaxel and CMF as adjuvant therapy

Track 10

BIG 2-98: Docetaxel concurrent with or sequential to anthracycline-based adjuvant therapy compared to
nondocetaxel-containing regimens

Track 11

Future direction of adjuvant chemotherapy clinical trials

Track 12

HER2 status predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer

Track 13

TOPO II as a predictive and prognostic marker in high-risk breast cancer

Track 14

Clinical implications of TOPO II aberrations


	Joanne L Blum, MD, PhD Director, Hereditary Cancer Risk Program and Research Site Leader Baylor-Charles A Sammons Cancer Center Dallas, Texas Click here to download the entire interview		MP3